Hannah Mabey

Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database

Albert Jang, Tanya Jindal, Ali Raza Khaki, Cindy Jiang et autres

us (code pays fourni par la source)

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3 -altered advanced urothelial cancer: analysis of the UNITE collaborative study

Cindy Jiang, Hyunsoo Hwang, Ilana Epstein, Dimitra Rafailia Bakaloudi et autres

BACKGROUND: Erdafitinib is approved for locally advanced/metastatic urothelial cancer (LA/mUC). As enfortumab vedotin (EV) plus pembrolizumab enters frontline management, outcomes with erdafitinib pre- and post-EV are clinically relevant but not specifically evaluated in clinical trials. METHODS: UNITE is a multi-institutional retrospective study …

us, in (code pays fourni par la source)

Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

Amanda Nizam, Charles B. Nguyen, Jinju Li, Emily C. Zabor et autres

INTRODUCTION: Enfortumab vedotin-ejfv (EV), an antibody-drug conjugate approved for advanced urothelial carcinoma (aUC), has limited real-world safety data and no validated predictive biomarkers. Retrospective studies suggest higher objective response rates (ORR) among patients developing EV-related dermatologic toxicities, but survival implications remain unclear. …

us (code pays fourni par la source)